Shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) rose 5.3% during mid-day trading on Friday. The stock traded as high as $166.31 and last traded at $167.8150. Approximately 617,670 shares changed hands during trading, a decline of 78% from the average session volume of 2,800,772 shares. The stock had previously closed at $159.43.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the company. Wedbush upped their target price on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. Piper Sandler boosted their price target on shares of Revolution Medicines from $210.00 to $222.00 and gave the stock an “overweight” rating in a research report on Thursday, November 5th. Stifel Nicolaus boosted their target price on Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Morgan Stanley cut their price objective on Revolution Medicines from $272.00 to $247.00 and set an “overweight” rating for the company in a research report on Friday, November 13th. Finally, Brookline Capital Markets started coverage on Revolution Medicines in a report on Monday, September 28th. They issued a “buy” rating and a $318.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $262.75.
Get Our Latest Stock Report on RVMD
Revolution Medicines Stock Up 1.2%
The company has a market cap of $34.89 billion, a price-to-earnings ratio of -17.65 and a beta of 1.44. The stock’s 50-day moving average is $190.87 and its 200-day moving average is $160.71. The company has a current ratio of 8.36, a quick ratio of 8.34 and a debt-to-equity ratio of 0.44.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.35) by $0.45. The firm had revenue of $197.56 million during the quarter, compared to the consensus estimate of $25.58 million. During the same quarter in the previous year, the firm earned ($1.61) earnings per share. On average, analysts anticipate that Revolution Medicines, Inc. will post -7.41 earnings per share for the current fiscal year.
Insider Buying and Selling at Revolution Medicines
In related news, Director Lorence Kim sold 56,000 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $203.24, for a total value of $11,381,440.00. Following the transaction, the director owned 17,090 shares of the company’s stock, valued at approximately $3,473,371.60. This trade represents a 76.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mark Goldsmith sold 13,988 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the sale, the insider directly owned 253,342 shares of the company’s stock, valued at approximately $50,475,860.08. This trade represents a 5.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 273,901 shares of company stock worth $53,970,418. 7.60% of the stock is owned by company insiders.
Institutional Trading of Revolution Medicines
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alphabet Inc. acquired a new stake in shares of Revolution Medicines in the second quarter valued at approximately $551,843,000. Assenagon Asset Management S.A. boosted its holdings in shares of Revolution Medicines by 987.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after acquiring an additional 1,980,699 shares in the last quarter. ABS Investment Management LLC purchased a new position in Revolution Medicines in the second quarter valued at about $337,104,000. Winslow Capital Management LLC acquired a new position in shares of Revolution Medicines during the 3rd quarter worth approximately $260,191,000. Finally, Bank of America Corp DE acquired a new position in Revolution Medicines in the 2nd quarter valued at $184,267,000. Institutional investors and hedge funds own 94.34% of the company’s stock.
Revolution Medicines Company Profile
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
See Also
- Five stocks we like better than Revolution Medicines
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
